TUSTIN, Calif., April 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection (HCV), today announced that the following preclinical abstracts will be the subject of oral and poster presentations at the 2008 Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego:

    --  "Targeting mutant p53 protein and tumor vasculature: An effective
        combination therapy for advanced breast tumors" (Abstract #2341, New
        Targets 1: Mechanisms Session) - Poster session scheduled for Monday,
        April 14, 2008 from 8:00 am to 12:00 pm.

    --  "An immunocytokine that binds to phosphatidylserine generates an
        effective cell-based tumor vaccine in mice" (Abstract #2841, Tumor
        Vaccines Session) - Poster session scheduled for Monday, April 14,
        2008 from 1:00 pm to 5:00 pm.

    --  "Combination of a monoclonal anti-phosphatidylserine antibody with
        docetaxel strongly inhibits the growth and metastasis of
        hormone-refractory prostate cancers in mice" (Abstract #2551, New
        Approaches to Biological Therapy Session) - Oral presentation
        scheduled for Monday, April 14, 2008 at 2:10 pm.

    --  "Antibody targeting of phosphatidylserine produces a cytokine
        microenvironment that enhances innate anti-tumor immune responses"
        (Abstract #4079, Immunoconjugates, Peptides, and Protein Therapeutics
        Session) - Poster session scheduled for Tuesday, April 15, 2008 from
        8:00 am to 12:00 pm.

Abstracts and information about the AACR and its Annual Meeting may be found at http://www.aacr.org.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

     Contacts:
     GendeLLindheim BioCom Partners
     Investors                              Media
     info@peregrineinc.com                  Barbara Lindheim
     (800) 987-8256                         (212) 918-4650

SOURCE Peregrine Pharmaceuticals, Inc.

http://www.peregrineinc.com

Copyright (C) 2008 PR Newswire. All rights reserved

News Provided by COMTEX